Befar en es it fr

Befar Brand names, Befar Analogs

Befar Brand Names Mixture

  • No information avaliable

Befar Chemical_Formula


Befar RX_link

Befar fda sheet

Befar FDA

Befar msds (material safety sheet)

Befar MSDS

Befar Synthesis Reference

No information avaliable

Befar Molecular Weight

354.481 g/mol

Befar Melting Point

115 - 116 oC

Befar H2O Solubility

26.7 mg/L

Befar State


Befar LogP


Befar Dosage Forms

Liquid; Powder for solution; Solution; Suppository

Befar Indication

For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

Befar Pharmacology

Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora. As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops. This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow.

Befar Absorption

The absolute bioavailability of alprostadil has not been determined.

Befar side effects and Toxicity

Oral, mouse: LD50 = 186 mg/kg; Oral, rat: LD50 = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage.

Befar Patient Information

Befar Organisms Affected

Humans and other mammals